NextCure reports FY2024 net loss of $55.7M; cash $68.6M, LNCB74 Phase 1 advancing

NextCure, Inc.

Net loss of $55.7M in FY2024 improved from $62.7M in FY2023; R&D expenses $41.5M, G&A $15.7M, both down YoY.
Cash, equivalents, and marketable securities $68.6M at Dec 31, 2024 (vs $108.3M); expected to fund operations into H2 2026.
LNCB74 (B7-H4 ADC) Phase 1: completed cohort 1 in Feb 2025, currently dosing cohort 2; backfill cohorts planned H2 2025.
Preclinical non-oncology programs (NC181 for Alzheimer's, NC605 for osteogenesis imperfecta) seeking partnerships.
Potential IND filings for NC181 and NC605 within 12-18 months if partner or third-party funding secured.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.